TELESIS BIO (TBIO)
(Delayed Data from NSDQ)
$4.38 USD
+0.55 (14.34%)
Updated Jul 10, 2024 03:59 PM ET
Pre-Market: $3.70 -0.68 (-15.51%) 9:26 AM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.38 USD
+0.55 (14.34%)
Updated Jul 10, 2024 03:59 PM ET
Pre-Market: $3.70 -0.68 (-15.51%) 9:26 AM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Sanofi (SNY) Gets FDA Approval for Sarclisa Label Expansion
by Zacks Equity Research
Sanofi's (SNY) Sarclisa gets FDA approval to treat multiple myeloma patients who have received one to three prior lines of therapy in combination with Kyprolis and dexamethasone.
Translate (TBIO) Down on Unsatisfactory CF Drug Study Results
by Zacks Equity Research
Translate Bio (TBIO) announces data from second interim analysis of phase I/II study evaluating MRT5005 in patients with cystic fibrosis. The candidate fails to improve lung function in patients.
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron Pharma, Sanofi, Novavax and Translate Bio
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron Pharma, Sanofi, Novavax and Translate Bio
Biotech Stock Roundup: REGN's Cancer Drug Positive, COVID-19 Updates From NVAX & More
by Zacks Equity Research
The biotech sector was in focus last week with vaccine and antibody updates from quite a few companies like Novavax (NVAX) and Vir (VIR), among others.
Sanofi (SNY)/Translate Bio COVID-19 Vaccine in Clinical Stage
by Zacks Equity Research
The phase I/II clinical study on Sanofi (SNY)/Translate Bio's (TBIO) COVID-19 vaccine candidate will assess its safety, immune response and reactogenicity.
Translate Bio, Inc. (TBIO) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Translate Bio, Inc. (TBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sanofi (SNY) Q4 Earnings & Sales Miss, 2021 EPS View Bright
by Zacks Equity Research
Sanofi's (SNY) Q4 earnings and sales miss estimates. Dupixent drives sales growth in the quarter
6 Biotech/Drug Stocks Up Manifold in 2020 Thanks to COVID-19
by Zacks Equity Research
We discuss six biotech/drug stocks, NVAX, VXRT, MRNA, TBIO, INO and BNTX that have more than doubled in 2020 on the back of their progress in coronavirus vaccine development.
The Zacks Analyst Blog Highlights: INO, NVAX, TBIO and VXRT
by Zacks Equity Research
The Zacks Analyst Blog Highlights: INO, NVAX, TBIO and VXRT
4 Biotechs Likely to Gain on Coronavirus Vaccine Efforts
by Indrajit Bandyopadhyay
In the race to develop a coronavirus vaccine, Pfizer and its partner BioNTech have a lead, closely followed by Moderna. However, four other biotechs, NVAX, TBIO, INO and VXRT, still hold potential to gain from their vaccine development efforts.
Sanofi's (SNY) Meningitis Vaccine MenQuadfi Wins EU Approval
by Zacks Equity Research
The European Commission nods to Sanofi's (SNY) MenQuadfi, a meningococcal vaccine for individuals, aged 12 months and older.
Find Strong Stocks with this First Profit Screener
by Benjamin Rains
Let's use our 'First Profit' screener to help find stocks that investors might want to consider buying after they posted positive earnings for the first time ever, or for some time...
Sanofi's (SNY) Q3 Earnings & Sales Miss, 2020 View Raised
by Zacks Equity Research
Sanofi's (SNY) earnings and sales miss estimates. It raises its earnings growth expectations for the year.
Sanofi's mRNA Vaccine for Coronavirus to Enter Clinical Stage
by Zacks Equity Research
Sanofi (SNY) and Translate Bio select coronavirus vaccine candidate MRT5500 for clinical development, based on its promising pre-clinical data. A clinical study is anticipated by this year-end.
Sanofi/Glaxo to Supply 70M Coronavirus Vaccine Doses in Canada
by Zacks Equity Research
Sanofi's (SNY) recombinant protein-based technology is being combined with Glaxo's pandemic adjuvant technology to develop an adjuvanted COVID-19 vaccine.
Sanofi/Glaxo to Supply 300M Coronavirus Vaccine Doses in EU
by Zacks Equity Research
Sanofi (SNY) recombinant protein-based technology is being combined with Glaxo's (GSK) pandemic adjuvant technology to develop an adjuvanted COVID-19 vaccine.
What's in Store for Avenue Therapeutics (ATXI) in Q2 Earnings?
by Zacks Equity Research
Avenue Therapeutics' (ATXI) sole pipeline candidate, tramadol, is under review. With lower clinical activities, operating expenses are likely to have declined during the second quarter.
What Awaits Selecta Biosciences (SELB) This Earnings Season?
by Zacks Equity Research
In the absence of any marketed drugs, investor focus is likely to be on Selecta Biosciences' (SELB) lead pipeline candidate, SEL-212 on the second-quarter conference call.
Aldeyra (ALDX) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Aldeyra's (ALDX) pipeline progress will be in focus when it reports Q2 results later in the week.
CytoDyn (CYDY) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
CytoDyn's progress on its lead candidate, leronlimab, will be in focus when it reports Q4 results.
Actinium (ATNM) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Actinium's (ATNM) lead candidate, Iomab-B, being evaluated for acute myeloid leukemia will be in focus when the company reports second-quarter earnings.
Onconova (ONTX) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on pipeline updates when Onconova (ONTX) reports Q2 results.
Is a Beat in the Cards for Bristol-Myers' (BMY) Q2 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2020 results.
Teva (TEVA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Teva's (TEVA) second-quarter conference call, investors will look for updates on the extent to which the coronavirus pandemic may have impacted sales of its products
Has Translate Bio (TBIO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (TBIO) Outperforming Other Medical Stocks This Year?